February 2026 HAL Allergy expanded manufacturing capabilities for allergen immunotherapy products to support growing demand across Europe and international markets.
October 2025 ALK launched additional allergy immunotherapy tablet indications in selected international markets, strengthening its respiratory allergy treatment portfolio.
July 2025 Stallergenes Greer expanded its allergen immunotherapy portfolio with new treatment options for respiratory allergies across European markets.
May 2025 Sanofi and Regeneron received U.S. FDA approval for Dupixent® (dupilumab) as the first targeted therapy for adults with uncontrolled chronic spontaneous urticaria (CSU), expanding its allergy treatment portfolio.